| Prev Close | 122.56 |
| Open | 122.55 |
| Day Low/High | 121.28 / 122.83 |
| 52 Wk Low/High | 61.61 / 115.14 |
| Volume | 4.73M |
Abbott Laboratories (ABT)
121.50
1.06
0.86
NYSE
| Exchange | NYSE |
| Shares Outstanding | 1771.53B |
| Market Cap | 214.43B |
| P/E Ratio | 60.02 |
| Div & Yield | N.A. (N.A) |
Latest News
Jim Cramer: There's Good Risk and Bad Risk
Here's the kind I like to buy -- and the vetted stocks that you can play on 'good' risk.
Here's a Quick Technical Update on Abbott Laboratories
Traders should continue to hold existing longs on ABT.
Underperforming Transports, Vaccine Delivery, FOMC Statement, 3 Trading Thoughts
Wednesday afternoon the Fed's Federal Open Market Committee will publish the central bank's first official policy statement of 2021.
Abbott Labs Has the Formula for a Long Trade
ABT has made an upside breakout on the daily Point and Figure chart, and here's how investors can make their next move.
Jim Cramer: You Just Won Powerball, Now What?
Remember, you only need to get rich once.
8 Quality Dividend Stocks for Durable Growth and Income
Four experts highlight their favorite dividend stocks for 2021.
Jim Cramer: Misconceptions About Covid-19 and Wagering on Its Longevity
Maybe we will be better when Covid 2021 comes around. But sustainable? Ha. How about inevitable?
Abbott Laboratories Could Soon Break Out From Its Sideways Pattern
Let's review the charts and indicators.
Jim Cramer: 8 Stocks That Benefit the Most If There's Another Modified Lockdown
These companies have spent the last six months preparing for a second lockdown betting it will occur.
Jim Cramer: Health Care Stocks, the Election and the Perfect Setup
Right now, the market is furiously trying to price in a Blue Wave, and the health care sector is getting clobbered. But here's how I think things play out.
Does Abbott Labs Still Pass My Test After Earnings?
Diagnostics revenue grew an impressive 38% due to the necessity of Covid-19 testing.
'Inside Day', Electoral Risk, Banking Stocks, Stimulus Immediately Needed
There is a presidential debate on Thursday. The market is being forced to adjust for renewed potential uncertainty.
Jim Cramer: This Is How Stocks Would Fare Under a President Biden
I don't pick stocks on politics, but was shocked to see how a majority of our Action Alerts PLUS holdings would perform if Joe Biden wins the White House.
Jim Cramer: Better to Mask and Test Than Wait for Vaccine
New rapid tests and the effectiveness of universal mask wearing give hope while we wait on the elusive vaccine.
Jim Cramer: Fly Ahead of the Pack on Boeing
People want to wait and see on this beleaguered aviation name, but I don't think you can do that. Here's why.
Jim Cramer: You Heard the Ugly of the Debate. Here's the Good.
Neither candidate seems to be the enemy of the market -- at least not yet.
Abbott Labs Stock Could Still Slip Lower
Let's review the charts and indicators.
Jim Cramer: Abbott's Rapid Covid-19 Test and My Super Bowl Dreams
Abbott Labs can bring back some normalcy to this country -- and the world -- with its BinaxNOW rapid antigen test along with its amazing Navica app.
This Dividend Stock's Got the Right Medicine for Investors
AbbVie stock is a rare combination of value, growth, and yield, making it a unique pick in the health care sector.
Charting the Best Hotels in the Sector
We grade Choice Hotels, Hilton and Marriott, and check on the opportunities each offers.
Rapid Test, Rapid Dow Rally?
Here's what I expect to happen to the market near term off this potentially game-changing development.
Jim Cramer: Abbott Labs and the Rally in Travel
ABT will end the issues of flying and cruising. Of course it's another story when you get there. But boarding will be solved.
If You Like Laggards, Here Are 3 to Consider
These companies will benefit immensely as the country experiences a burst of economic growth.
Market Continues Higher in Front of Big Stock Splits and Dow Rebalancing
There is major rotational action taking place but the flood of liquidity is preventing any real downside from developing.
Vaccine Chills, Divergent Trails, Fed-flation, Walmart and TikTok: Market Recon
Plus, Veeva Systems reports stellar results and ups its guidance.
Rotation Unravels Speculative Plays
Speculative trading in lower-priced stocks has dried up and the small caps have been much tougher.
Jim Cramer: Here Comes the Biggest Test Yet
As the president pins all hopes on a Covid vaccine and shuns tried-and-true prevention efforts, Abbott is offering a rapid test that could be a game changer.
